A New Drug-Eluting Stent on the Horizon

Everolimus-eluting stents perform well in a comparison with paclitaxel-eluting stents, setting the stage for FDA approval and — more important — long-term outcome studies.

Manufacturers of drug-eluting stents (DES) strive to improve device safety and efficacy. Three DES are now available in the U.S., and even more are available in other countries. Based on the results of this manufacturer-sponsored, randomized, multicenter trial, the everolimus-eluting stent (EES) is poised to become the next entry into the U.S. market.

A total of 1002 patients undergoing elective PCI for one or two de novo lesions were randomized to receive an EES or a paclitaxel-eluting stent (PES) at a two-to-one ratio. Of 564 patients who were assigned to receive angiographic follow-up at 8 months, results were available for 77%. At 8 months, in-segment late loss (the primary endpoint) was 0.14 mm in the EES group versus 0.28 mm in the PES…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI